Buparvaquone

About Haorui Products Technology Contact

Buparvaquone API

 

Haorui supplies high quality Buparvaquone API produced by our GMP facility that has been successfully inspected by the FDA. We offer competitive prices and support our products with reliable technical and regulatory services.  Buparvaquone API is available from R&D to commercial quantities. Please contact us for more details.

  The following information is provided for general information purposes ONLY.

Buparvaquone Description

Buparvaquone is a hydroxynaphthoquinone antiprotozoal drug related to parvaquone and atovaquone. It is a promising compound for the therapy and prophylaxis of all forms of theileriosis. Buparvaquone has been shown to have anti-leishmanial activity in vitro.

It is the only really efficient therapy in bovine theileriosis, where it is used since the late 1980s

Buparvaquone Use in bovine theileriosis

At unique dose of 2,5 mg/kg, recovery rate of curable cases is 90 to 98 %. In tropical theileriosis, a dosage of 2.0 mg/kg has the same efficiency. Body temperature returns to normal in two days (but only after 5 days in some cases). Parasitemia lowers from 12 % (D0) to 5 % (D1), than to 1 % (D5) and is nul at D7.

Chemical Structure

Molecular Formula C21H26O3

Buparvaquone Patents 1
Haorui - Your Partner to Pharmaceutical Success - Copy Right Reserved